Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reassessment of statin-associated muscle symptoms in familial hypercholesterolemia
2025-521589-83-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atorvastatin in familial hypercholesterolemia (FH), sponsored by Oslo University Hospital. Primary endpoint: Individual mean difference in muscular symptom intensity. Planned start May 2026; status: authorised.
02
Drugs
atorvastatin
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2025-521589-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521589-83-00.